Halozyme Therapeutics, Inc. Third Quarter 2024 Financial & Operating Results 1 NASDAQ: HALO October 31, 2024 Forward Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future growth, financial performance (including the Company's 2024 guidance and longer term financial outlook through 2028) and expectations for profitability, revenue (including e ...

Halozyme Therapeutics (HALO) reported $290.08 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 34.3%. EPS of $1.27 for the same period compares to $0.75 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $248.01 million, representing a surprise of +16.97%. The company delivered an EPS surprise of +28.28%, with the consensus EPS estimate being $0.99.While investors closely watch year-over-year changes in headline numbers -- revenue an ...

Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 28.28%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.78 per share when it actually produced earnings of $0.91, delivering a surprise of 16.67%.Over the last fou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its char ...

Exhibit 99.1 HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million GAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.27 Raised 2024 Financial Guidance Ranges for Total Revenue of $970-$1,020 million, Representing YOY Growth of 17%-23%, Adjusted EBITDA of ...

Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 millionNet Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 millionGAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.271Raised 2024 Financial Guidance Ranges for Total Revenue of $970-$1,020 million, Representing YOY Growth of 17%-23%, Adjusted EBITDA of $595-$625 million, Representing YOY Growth of 40%-47%, and Non-GAAP Diluted EPS of ...

Company Projects No Impact on U.S. or European Royalty Revenues from DARZALEX FASPRO® and SC through 2032Reiterates 2024 Royalty Revenue Guidance of $520-555 million and Expectations to Generate >$1 billion in 2027Conference Call Scheduled Today, Thursday, October 24 at 5:30am PT/8:30am ETSAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update following a decision by the Opposition Division of the European Patent Office ("EPO") to revoke one of the Jansse ...

SAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and operating results on Thursday, October 31, 2024, following the close of trading.Halozyme will host a conference call on Thursday, October 31, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813747.A live webcast and re ...

Wells Fargo has downgraded its rating for Halozyme Therapeutics (HALO, Financial), a U.S. biotechnology company, from "Overweight" to "Equal Weight," with a target price set at $62, indicating limited upside potential. This year, Halozyme's stock has surged by 50%, compared to the S&P 500's approximately 21% rise. As of the close of trading on Monday, Halozyme's shares fell 9% to $53.85. While new product launches present a reason for holding Halozyme stock, Wells Fargo believes that market expectations alr ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Halozyme Therapeutics (HALO) , which belongs to the Zacks Medical - Biomedical and Genetics industry. When looking at the last two reports, this biopharmaceutical company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 15.58%, on average, in the last two quarters. For the most recent quarter, Halozyme Therape ...